BioVersys AG (XSWX:BIOV) Other Long-Term Liabilities: CHF-0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BIOV BioVersys AG XSWX:BIOV
4 GF Score
Price CHF25.20
View Full Analysis

What is BioVersys AG Other Long-Term Liabilities?

BioVersys AG XSWX:BIOV +0.40% 4 Other Long-Term Liabilities is CHF-0.00 Mil as of Dec. 2025. GuruFocus rates XSWX:BIOV with a GF Score™ of 4/100.

BioVersys AG's other long-term liabilities for the quarter that ended in Dec. 2025 was CHF-0.00 Mil.

BioVersys AG's quarterly other long-term liabilities increased from Dec. 2024 (CHF0.00 Mil) to Jun. 2025 (CHF0.00 Mil) but then declined from Jun. 2025 (CHF0.00 Mil) to Dec. 2025 (CHF-0.00 Mil).

BioVersys AG's annual other long-term liabilities increased from . 20 (CHF0.00 Mil) to Dec. 2024 (CHF0.00 Mil) but then declined from Dec. 2024 (CHF0.00 Mil) to Dec. 2025 (CHF-0.00 Mil).

BioVersys AG Other Long-Term Liabilities Related Terms

BioVersys AG Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for BioVersys AG's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG Other Long-Term Liabilities Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
Other Long-Term Liabilities
0.00 -0.00

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
Other Long-Term Liabilities 0.00 0.00 0.00 -0.00
XSWX:BIOV
4GF Score
BioVersys AG XSWX:BIOV
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of CHF-0.00 Mil mean?
BioVersys AG (XSWX:BIOV) has a Other Long-Term Liabilities of CHF-0.00 Mil as of Dec. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on BioVersys AG and its competitors.
Is BioVersys AG's Other Long-Term Liabilities too high?
BioVersys AG's current Other Long-Term Liabilities is CHF-0.00 Mil. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's Other Long-Term Liabilities compare to VRTX and REGN?
BioVersys AG's Other Long-Term Liabilities of CHF-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on BioVersys AG and its competitors. BioVersys AG's current Other Long-Term Liabilities is CHF-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current Other Long-Term Liabilities of CHF-0.00 Mil. The current Other Long-Term Liabilities is CHF-0.00 Mil. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current Other Long-Term Liabilities is CHF-0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKW33:Germany
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score

Get the complete analysis for XSWX:BIOV

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF25.20
Price